Pharmafile Logo
Pharmafocus logo
Advanced Search

Cardiology

Showing 15 posts of 50 posts found.

NHS accepts Pfizer’s tafamidis for ATTR-CM treatment

May 14, 2024
Medical Communications ATTR-CM, Cardiology, NHS, Pfizer, tafamidis

NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM).

News

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024
Medical Communications COPD, Cardiology, clinical trial, verona pharma

Verona Pharma has announced that it will share eight posters at the American Thoracic Society International Conference (ATS) 2024, including …

News

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024
Research and Development Bayer, Cardiology, cardio, cvd

Bayer and Evotec have announced that they have updated the focus of their collaboration to work on the development of …

News

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024
Research and Development Cardiology, Sanofi, clinical trial, thrombocytopenia

Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib 400mg twice daily oral treatment …

News

Johnson & Johnson to acquire Shockwave Medical

April 8, 2024
Business Services Cardiology, Johnson & Johnson, Shockwave Medical, acquisition

Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a definitive agreement under which J&J …

News

FDA approves Eko Health’s AI for heart failure detection

April 3, 2024
Medical Communications Cardiology, Eko Health, FDA, heart failure, low ejection fraction

Eko Health has announced that the US Food and Drug Administration (FDA) has approved its Low Ejection Fraction (Low EF) …

News

FDA approves Merck’s Winrevair for PAH treatment

March 27, 2024
Medical Communications Cardiology, FDA, Merck, Winrevair, pulmonary arterial hypertension

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

News

FDA approves J&J’s Opsynvi for PAH treatment

March 25, 2024
Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …

News

FDA approves Idorsia’s Tryvio for treatment of high blood pressure

March 22, 2024
Medical Communications Cardiology, FDA, Tryvio, blood pressure, blood presure, hypertension

Idorsia has announced that the US Food and Drug Administration (FDA) has approved Tryvio (aprocitentan) for the treatment of hypertension …

News

Tenax Therapeutics enrolls first patient in phase 3 trial for pulmonary hypertension treatment

February 8, 2024
Research and Development Cardiology, Tenax Therapeutics, clinical trial, pulmonary hypertension

Tenax Therapeutics has announced that it has enrolled the first patient in its phase 3 LEVEL study, which aims to …

News

AstraZeneca shares results from phase 3 trial of acoramidis in adults with ATTR-CM

February 2, 2024
Research and Development ATTR-CM, AstraZeneca, Cardiology, acoramidis, clinical trial

AstraZeneca has announced positive high-level results from the phase 3 trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) …

News

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023
Medical Communications COPD, Cardiology, Dupixent, Sanofi, clinical trial

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for Dupixent as a treatment for …

News

Acesion Pharma raises €45m series B funding

September 26, 2023
Business Services Acesion Pharma, Cardiology, atrial fibrillation, series B financing

Acesion Pharma has announced that it has closed an oversubscribed €45m series B financing round. This financing was co-led by …

News

Novo Nordisk acquires Embark Biotech and its lead metabolic programme

August 31, 2023
Business Services Cardiology, Novo Nordisk, Obesity, acquisition, metabolics, obesity

Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset metabolic programme. The teams will …

News

AstraZeneca’s Forxiga approved in China for chronic heart failure treatment

August 18, 2023
Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure

AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025